“Success against #COVID19 will likely require both vaccines & treatments,” Pfizer CEO Albert Bourla said on Wednesday. “We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate-specifically designed to combat SARS-CoV-2-in non-hospitalized, low-risk adults.”
link